Hepatitis C virus (HCV) antibodies were detected in 85.9% of the samples by commercial enzyme immunoassay (EIA) kits. Most EIA-positive samples were reactive (80%) by the RIBA HCV test (Ortho Diagnostics). Samples with optical density values .2.0 were mostly reactive (87%) by RIBA HCV test, in contrast to those with values '1.0 (6.6%). Samples which were indeterminate by the RIBA HCV test were positive (88.4%) by HCV neutralization EIA (Abbott Laboratories), along with 29.4% of samples which were nonreactive by the RIBA HCV test.
The cloning and expression of the hepatitis C virus (HCV) genome (2) have opened the way for the development of an assay (5) for the detection of antibody to HCV (anti-HCV). Two commercial anti-HCV enzyme immunoassay (EIA) kits are available (Abbott Laboratories, North Chicago, Ill., and Ortho Diagnostics, Inc., Raritan, N.J.) under license from Chiron Corporation (Emeryville, Calif.). Problems with the specificity of EIAs for HCV antibody have been encountered, and false-positive results due to antibodies to human superoxide dismutase (SOD) (4), rheumatoid factor (8) , and hyperglobulinemia (1, 6) have been reported. The specificity problem has also been reported for blood donors for whom only 19% of EIA repeat-positive samples were confirmed (7) .
Both companies have also developed supplementary tests to confirm EIA-positive samples. Ortho Diagnostics has developed an immunoblot assay (Chiron RIBA HCV test) in which recombinant antigens c100-3 and 5-1-1 and human SOD are immobilized as individual bands on nitrocellulose strips. Abbott Laboratories has developed a neutralization EIA in which c100-3 in solution is used to block anti-HCV from binding to solid-phase antigen (c100-3).
In this report, we describe the comparative performances of the commercial EIAs and supplementary tests for the detection of anti-HCV in a panel of human serum samples.
Serum specimens from high-risk groups (40 intravenous drug abusers, 77 prisoners, 109 hemodialysis patients [297 samples], 86 homosexuals, and 335 hepatitis patients negative for recent infection with hepatitis A or B virus) and from a low-risk control group (256 federal public servants) were tested for anti-HCV by both commercially available screening EIAs. Sexual orientations and histories of drug use were not determined for all of the groups.
The screening assays are both sandwich-type EIAs. In the Ortho EIA, recombinant antigen (clOO-3) was coated on microwells, whereas polystyrene beads were used by the Abbott EIA. The other minor differences between these tests were the sample size and dilution factor. Twenty and 10 ,ul of sample were used by the Ortho Diagnostics and Abbott Laboratories EIAs, respectively. The Abbott EIA used a more diluted sample (1:41) than the Ortho EIA (1:11). The samples were tested according to the respective protocols.
The results showed that the performances of both tests for the detection of anti-HCV were similar (Table 1) . A total of 1,091 samples were tested by EIA, and 241 (22.0%) were * Corresponding author.
positive for anti-HCV by at least one test. Among the anti-HCV-positive samples, 207 (85.9%) were positive by both tests and 17 samples each were positive by only one test. Thus, 34 samples (14.1%) had discordant results. This difference was unexpected, as both tests were using the same antigen (c100-3). These results indicated that there were some differences in the performance of the two EIAs, as they detected some samples independent of each other.
The specificities of the EIAs were further evaluated by testing the repeatable EIA-positive samples by RIBA HCV assay. A total of 105 samples positive by both EIAs and all 34 samples giving discordant results were tested by the RIBA HCV assay. The assay was performed and interpreted according to the recommended protocol. Reaction to both c100-3 and 5-1-1 antigens was considered positive, whereas no reaction to either band was considered negative. Reaction to only one of the antigen bands was considered indeterminate. Reactivity to the SOD band alone was considered negative, but reactivity to SOD and to c100-3 and/or 5-1-1 was considered indeterminate. Results (Table 2) showed that 80% of samples positive by both EIAs were reactive by RIBA HCV assay. None of the 34 samples positive by only one test were reactive by the RIBA HCV assay. A total of 10.5% of the samples were indeterminate, and 8.6% were nonreactive. The number of reactive samples also varied in different groups. Samples from the prisoners and homosexuals were all reactive by the RIBA HCV test. Among (Table 3) A comparison of the RIBA HCV assay (Ortho Diagnostics) and the HCV neutralization EIA (Abbott Laboratories) was made by testing 61 EIA repeat-positive samples (both EIAs) by the two supplemental tests. In the HCV neutralization EIA, antigen c100-3 was used to block the binding of anti-HCV to the antigen bound to the solid phase. There was no SOD control, and antigen 5-1-1 was not used separately. A sample was considered positive for anti-HCV by neutralization test when the OD value for antigen (clOO-3)-treated specimens was reduced by 50% or The differences in the performances of these two tests are significant, and we are at a loss to explain why. We have not seen any report on a comparative evaluation of these two supplemental tests for anti-HCV.
The data indicated that the two commercial EIA kits for the detection of anti-HCV have similar performances, although significant differences between the RIBA HCV test and the HCV neutralization EIA were observed.
